Brain Scientific Announces Release of Improved NeuroCap(TM) and New US Distribution Deal with D&D Medical
Improvements to product and distribution aimed at satisfying growing customer demand
LAKEWOOD RANCH, Fla., Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSF), a Florida-based medical device technology company, announces today the immediate release of the improved and updated NeuroCap™ device and the signing of a distribution partnership with D&D Medical, Inc., to sell the company’s neurology devices in Tennessee, Kentucky, Indiana, and West Virginia.
D&D Medical, Inc., brings innovative medical technologies to market by educating medical professionals in their use and distributing them to where they are needed most.
“The NeuroCap makes EEG testing more comfortable for patients and efficient for clinicians,” said Don Sizemore, President of D&D Medical, Inc. “When I was introduced to the NeuroCap, and tested it in the field, I knew that it would make a big difference in the lives of patients needing neurological testing and the clinical staff carrying out their EEG exams.”
NeuroCap satisfies the three criteria D&D Medical uses to select new technologies to represent: it provides a safer alternative for the patients and clinicians, it’s innovative and new, and it saves hospitals and patients money.
Brain Scientific’s newly improved NeuroCap recently entered production for the company and its distributors to build stock and fulfill customer requests. The improvements to the NeuroCap include a proprietary gel with better conductivity, improved performance adhesive pads, a more conductive, precise ink formulation, and a base of modern blue PET material.
“Our improved NeuroCap is a more comfortable, easy-to-use, and efficient way to conduct EEG exams,” said Hassan Kotob, chairman and CEO of Brain Scientific. “The disposable NeuroCap, which is available for immediate shipping, allows clinicians to save prep time and see more patients, accelerating the timeline to results for critical EEG exams.”
Brain Scientific developed the NeuroCap to streamline EEG prep, testing and diagnosis. NeuroCap has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system.
The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. It allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap can be used in nearly any environment, including rural hospitals, ambulances, private practices and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific's corporate strategy, products, or investor relations, please visit brainscientific.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.